CASI Pharmaceuticals Inc
CASI
Company Profile
Business description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Contact
No. 81, Jianguo Road
Room 1701-1702, China Central Office Tower 1
Huamao Office Building, Chaoyang District
Beijing100025
CHNT: +86 01065618789
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
233
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,723.50 | 17.90 | -0.20% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,157.85 | 13.81 | -0.03% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,530.48 | 292.74 | 1.26% |
| NASDAQ | 19,424.07 | 122.21 | -0.63% |
| Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,960.47 | 20.40 | -0.34% |
| S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
| SSE Composite Index | 3,359.90 | 2.21 | -0.07% |